CAR T cells have already reshaped cancer treatment. Now, a new review argues that their immunosuppressive cousins – CAR Tregs – could open a very different therapeutic frontier: slowing neurodegeneration by restoring immune balance in the brain.
Rather than attacking diseased cells, regulatory T cells suppress damaging inflammation and promote tissue repair. Stein and Gendelman describe how this could be especially valuable in disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and multiple sclerosis, where chronic neuroinflammation is increasingly seen as a driver of neuronal injury. In these diseases, misfolded proteins or autoimmune responses can activate microglia, recruit inflammatory T cells, and create a cycle of tissue damage that Tregs may be able to interrupt.
The review highlights early preclinical evidence for antigen-specific CAR Tregs targeting amyloid-beta, tau, myelin proteins, and mutant SOD1. In animal models, these engineered cells have delayed disease onset, reduced inflammatory markers, promoted remyelination, or suppressed pathogenic immune activity. The appeal is clear: instead of broadly suppressing immunity, CAR Tregs could be directed precisely to diseased tissue or even specific pathogenic proteins.
But the field remains early. The authors note several major translational hurdles, including maintaining Treg lineage stability, choosing the right antigen, crossing the blood-brain barrier, avoiding excess immunosuppression, and ensuring long-term survival without exhaustion. Even so, the message of the review is optimistic: with the basic CAR-T playbook now established, CAR Tregs may offer a plausible next-generation cell therapy platform for neurological disease.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
